____________________________________________________________ 

Organising Committee

Parth leads the Diabetes Research Unit and the Type 1 Diabetes clinical service at the Queen Elizabeth Hospital. He is the author of over 100 peer-reviewed publications including publications that have been cited by international bodies on Type 1 diabetes and its management. He has served on the Diabetes UK Research Committee and was previously on the Research Advisory Board of the Diabetes Research and Wellness Foundation and Regional Advisory Committee for the NIHR RfPB programme. He was previous chair of the Academic subcommittee of The Association of British Clinical Diabetologists having led and supported the setting up of its first research grant funding scheme and national Diabetes Update training programme for doctors specialising in diabetes and endocrinology.

Parth reviews for all the major national and international diabetes journals. He contributes to the NIHR Horizon Scanning, and NICE Medical Technology reviews for new therapies.

Colin Dayan

Professor of Clinical Diabetes and Metabolism

Cardiff University School of Medicine. Senior Clinical Researcher, University of Oxford

Colin Dayan trained in medicine at University College, Oxford, and Guy’s and Charing Cross Hospitals in London, UK before obtaining a PhD in the immunology of Graves’ Disease in the Laboratory of Marc Feldmann. He then spent a year as an endocrine fellow at the Massachusetts General Hospital in Boston, USA before completing his specialist training in diabetes and endocrinology as a Lecturer in Bristol. In 2010, he was appointed to the Chair of Clinical Diabetes and Metabolism and Head of Section at Cardiff University School of Medicine and in 2020 as part-time Senior Clinical Researcher in the Nuffield Department of Medicine at the University of Oxford. 

Prof Dayan has a long-established interest in translational research in the immunopathology of type 1 diabetes promoting progress to “insulin free T1D”. He has published first-in-man clinical studies on the development of peptide immunotherapy and the use of nanoparticles in T1D as well as pioneering the use of lymph node and injection site sampling to monitor the response to therapy. Since 2015 he has been a leading member of the UKT1D-Research Consortium which has hosted more than 15 clinical trials in early T1D over 30 sites. He is currently leading on novel trial designs including the T1D Plus platform trial in Europe and Australia to rapidly test combinations of therapies. In collaboration with the Critical Path Institute, he led the TOMI consortium of 21 clinical trials to define the relationship between C-peptide preservation and clinical endpoints and build an FDA/EMA approved clinical trial simulation tool. He is now seeking to define novel endpoints in preclinical T1D as part of the EDENT1FI European programme. Prof Dayan is a committed advocate to finding ways to bring beta cell preservation and delaying the need for insulin therapy into routine clinical practice. In this regard he supported the application for regulatory approval of Tzield to the FDA in 2021 and is working with colleagues to introduce immunotherapy and population screening into the UK.

Theodora Papanikolaou

Clinical Research Fellow, University of Birmingham 

Theodora Papanikolaou graduated from the School of Medicine, Aristotle University of Thessaloniki, in Greece in 2011. She completed Specialty Training in General Paediatrics in the UK in February 2023 and has since worked as a Senior Clinical Fellow in the Paediatric Endocrinology and Diabetes department at Birmingham Children’s hospital.

Lauren Quinn

Clinical Research Fellow, University of Birmingham